EQRX — EQRx Income Statement
0.000.00%
HealthcareSpeculativeMid Cap
- $1.14bn
- -$71.09m
Annual income statement for EQRx, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | |
---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | PROSPECTUS | 10-K | 10-K |
Standards: | USG | USG | USG | USG |
Status: | Final | Final | Final | Final |
Total Revenue | 0 | 0 | 0 | 0 |
Selling / General / Administrative Expenses | ||||
Research And Development | ||||
Total Operating Expenses | 4.63 | 250 | 196 | 356 |
Operating Profit | -4.63 | -250 | -196 | -356 |
Total Net Non Operating Interest Income / Expense | ||||
Other Net Non Operating Costs | ||||
Net Income Before Taxes | -8.51 | -250 | -100 | -169 |
Net Income After Taxes | -8.51 | -250 | -100 | -169 |
Net Income Before Extraordinary Items | ||||
Net Income | -8.51 | -250 | -100 | -169 |
Income Available to Common Shareholders Excluding Extraordinary Items | ||||
Income Available to Common Shareholders Including Extraordinary Items | ||||
Diluted Net Income | -8.51 | -250 | -100 | -169 |
Diluted Weighted Average Shares | ||||
Basic EPS Including Extraordinary Items | ||||
Diluted EPS Including Extraordinary Items | ||||
Diluted EPS Excluding Extraordinary Items | ||||
Normalised Income Before Taxes | ||||
Normalised Income After Taxes | ||||
Normalised Income Available to Common Shareholders | ||||
Diluted Normalised EPS | -0.017 | -0.513 | -0.213 | -0.357 |
Dividends per Share |